Log In
Print this Print this

CD19-CAR gene therapy

  Manage Alerts
Collapse Summary General Information
Company Takara Bio Inc.
DescriptionChimeric antigen receptor (CAR) targeting CD19
Molecular Target CD19
Mechanism of ActionGene therapy
Therapeutic ModalityCell therapy: Non-stem cell
Latest Stage of DevelopmentPhase I/II
Standard IndicationNon-Hodgkin's lymphoma (NHL)
Indication DetailsTreat non-Hodgkin's lymphoma (NHL)
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today